MNC pharma: Seek opportunity! - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MNC pharma: Seek opportunity!

Nov 24, 2004

According to newspaper reports, a leading consultancy firm has estimated that the Indian pharmaceutical sector will become a US$ 25 bn industry by the year 2012, up from its current levels of about US$ 6.5 bn. According to the report, while the market in India will expand, further growth will be driven by exports of pharmaceutical products. While Indian companies are likely to grab this opportunity with both the hands, in this article we have tried to understand how MNC pharma companies are poised to benefit from this opportunity by analyzing their recent performance. There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others operate merely as a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies.

In the chart above, we can see that these companies have shown impressive performance in terms of growth, which is more in line with the market growth rate. While the consolidated growth of these five companies in the first nine-months of 2004 is about 11%, some have outperformed the others. While MNC companies largely have shied away from introducing new products, Novartis and Aventis have taken lead in last two years by launching new products in the Indian markets even before the new patent regime is in place.

However, the new patent regime that will come into force from 2005 will be significant for these MNC pharma companies, which are preparing themselves for the same. Most of the foreign companies have restructured themselves, be it Glaxo, Pfizer or Novartis to take advantage of the new patent regime. Although, the new patent regime will come in force from 2005, we do not see any significant impact in the topline of these companies in first two years (2005 and 2006). But in the long run, these MNC companies will certainly gain market share in high value patented products.

Apart from this, the other opportunity that exists for MNC companies in India is outsourcing. Most companies in western regulated markets are facing severe price competition from the low cost generics manufactured in India. These global corporations are likely to look at cutting costs by out-sourcing their manufacturing to low cost countries such as India and presumably, the best choice for them would be their own subsidiaries. The example of this phenomenon is Aventis, which is already making bulk drugs for its parent company. In fact, 22% of Aventis revenues are from outsourcing activity. Similarly, in case of Glaxo, it is supplying drugs manufactured in India to its parent company.

Be it selling new drugs in Indian markets or supplying drugs to their parent companies in western world, Indian arms of the global pharma giants are in for a change in their growth pattern in next few years. While the markets have realised this, there are still opportunities available for long-term investors to invest in the sector's growth trajectory.

Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

2 Responses to "MNC pharma: Seek opportunity!"

d. jacob soundararaj

Feb 19, 2011

Competent & seasoned professional with over 25 years of well- honed experience in business development, marketing, channel management, team management & brand promotion in the Pharmaceutical Industry with excellent understanding of business dynamics and updated market knowledge combined with creative strategies.

Seeking a position south india based (Bangalore) covering south india

Like 

dheeman das

May 7, 2009

I am Fresher need a job in any Pharma MNC companies in any field either in market production.

Like 
  
Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 3, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS